Cree BA, Selmaj KW, Steinman L, Comi G, et al. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Mult Scler 2022 Jun 28:13524585221102584. doi: 10.1177/13524585221102584.
PMID: 35765217